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Background. Human papillomavirus (HPV) vaccine prevents cervical pre-cancers and cancers caused by HPV
types 16 and 18. This study provides information on the HPV types detected in cervical cancers of Alaska
Native (AN) women.
Methods. Cases of invasive cervical cancer diagnosed in AN women aged 18 and above between 1980 and
2007 were identified from the Alaska Native Tumor Registry. A representative formalin-fixed, paraffin-
embedded archived pathology block was retrieved and serially sectioned to allow histologic confirmation
of lesion (first and last sections) and PCR testing of intervening sections. Extracted DNA was tested for
HPV using Linear Array HPV Genotyping Test (Roche Diagnostics) with additional INNO-LiPA HPV
Genotyping Assay (Innogenetics) testing on negative or inadequate specimens. All specimens were tested for a
minimum 37 HPV types.
Results. Of 62 cervical cancer specimens evaluated, 57 (91.9%) contained one or more HPV types. Thirty-eight
(61.2%) cancers contained HPV types 16 or 18, and 18 (29%) contained an oncogenic type other than type
16 or 18.
Conclusions. Overall, almost two-thirds (61.2%) of the archived cervical cancers had detectible HPV types 16
or 18, a finding similar to studies of US women. As expected, a proportion of cancers would not be prevented
by the current vaccines. HPV vaccination and cervical cancer screening are important prevention strategies
for AN women.
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T
here are an estimated 11,000 cervical cancers
each year in the United States; the cervical cancer
burden among Alaska Native (AN) women is 10.3
per 100,000 and ranks 8th in the number of cancer
diagnosed in AN women. Cervical cancer rates were four
times higher in AN women than in US white women during
the 1970s to early 1980s, but, through increased screening
and treatment activities, rates have since decreased to be
similar to the overall US average (1). HPV vaccines offer
new opportunities for primary prevention of these cancers;
both the bivalent HPV vaccine (Cervarix, GSK) and the
quadrivalent HPV vaccine (Gardasil, Merck) are licensed
and recommended for routine use in 11- or 12-year-old
girls for the prevention of cervical cancer (2).
Infection with HPV causes virtually all cervical squa-
mous cell carcinomas and cervical adenocarcinomas
(35). Studies of invasive cervical cancers demonstrate
that up to 99% of cervical cancer specimens have HPV
detected (47). Of approximately 40 HPV types identified
in the genital tract, at least 15 are considered carcinogenic
(7). In the United States and worldwide, more than
two-thirds of cervical cancers are due to HPV 16 and
18 (6,8). While studies have evaluated different regions
and countries, few have described genotypes in specific
populations. A prior study of cervical cancer specimens
from 1980 to 1989 found that HPV 16 was the most
prevalent genotype in AN women: prevalence of HPV 16
was 77% in AN, 81% in Greenland Natives and 70% in
Danish whites (9). In this study, 43% of HPV-positive AN
specimens contained multiple HPV genotypes compared
to 4% in Greenland Natives and 8% in Danish whites.
HPV 31 and 33 were more frequently detected in AN
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specimens (21 and 30%, respectively) than in specimens
from Greenland Native (3% each HPV 31 and 33) or
Danish white (0% HPV 31 and 6% HPV 33).
Our study assessed HPV genotypes found in invasive
cervical cancer specimens from AN women diagnosed
from 1980 to 2007. The purpose was to characterize the
preventable burden of HPV-associated cervical cancers
in AN women to assess the potential impact of HPV
vaccination on cervical cancer in this population.
Methods
Invasive cervical cancer diagnosed from 1980 to 2007
in AN women living in Alaska aged 18 years and older
were identified through the Alaska Native Tumor Reg-
istry (10). One representative formalin-fixed, paraffin-
embedded block of the primary tumor was selected from
each case at the Alaska Native Medical Center (ANMC).
Serial sections were cut using precautions to prevent HPV
contamination between blocks. The first and last sections
were stained with hematoxylin and eosin, and they were
reviewed by a study pathologist to confirm the histology.
An intervening 10-micron section was extracted using
the previously described high-temperature xylene-free
method yielding a 100-mL extract (11). All extracts were
tested with the Linear Array HPV Genotyping Test
(Roche Diagnostics), which detects 37 HPV types (6, 11,
16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51, XR(52), 53, 54,
55, 56, 58, 59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 73,
81, 82, 83, 84, 89, IS39) and includes b-globin as an
endogenous control. Samples with negative or inadequate
(HPV and b-globin negative) results were re-tested with
the INNO-LiPA HPV Genotyping Assay (Innogenetics).
LiPA detects 29 HPV types (6, 11, 16, 18, 26, 31, 33, 35,
39, 40, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 66, 68, 69, 70,
71, 73, 74, 81, 82) and includes HLA-DPB1 as an
endogenous control. Inadequate samples (HPV negative
and endogenous control negative) in both assays were
excluded from this analysis. Fifteen HPV genotypes 16,
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 and 82 are
considered oncogenic in this analysis (7). The protocol
was approved by the Alaska Area IRB, Southcentral
Foundation Scientific Review Board and the Alaska
Native Tribal Health Review Board.
Results
From 1980 to 2007, a total of 139 AN women were
diagnosed with invasive cervical cancer while a resident of
Alaska. Among these, a total of 136 were ]18 years of
age and 90 were diagnosed at the ANMC in Anchorage,
Alaska. Archived tissues were located for 71 (79%) of
ANMC cases 18 years and 62 (69%) contained
representative cervical tumor.
The median age of the 62 women with an archived
specimen available was 41 years, the same as the median
age for all AN women diagnosed with invasive cervical
cancer during the period 19802007 (Table I). Among
women diagnosed during years 19842007, for which
SEER Summary Stage was available, stage at diagnosis
was similar (local, regional, distant and unknown stages)
to all AN women diagnosed with invasive cervical cancer.
Year of diagnosis was similar except for years 19851989
when proportionately fewer specimens were available.
The majority of specimens were for women from Ancho-
rage (47%) and women from the Yukon-Kuskokwim area
(24%) of Alaska who presented or were referred to the
Anchorage facility than for women living in other areas
of Alaska.
All 62 tissue specimens available for HPV typing
yielded adequate results: 57 (91.9%) had HPV detected;
56 (90.3%) specimens were positive for one or more
HPV types considered oncogenic (Table II). HPV 16 was
detected in half of all specimens (31/62, 50%) and HPV
16 or 18 were detected in 61.3% (38/62) of specimens.
Table I. Age, ethnicity, tumor stage, diagnosis year and
geographic distribution of Alaska Native women with invasive
cervical cancer, and Alaska Native women with cervical cancer
specimens available, 19802007
Age range (years) 1689 2380
Mean 42.5 44.4
Median 41 41
Ethnicity (n62) % %
Inupiaq/Yupik 43.9 54.8
Athabascan 44.6 30.6
Aleut 11.5 14.5
SEER summary stage % %
Local 58.7 52.0
Regional 28.4 36.0
Distant 10.1 12.0
Unknown 2.7 0
Year of diagnosis % %
19801984 25.5 24.3
19851989 21.9 11.2
19901994 16.3 17.7
19951999 14.2 17.7
20002004 9.9 12.9
20052007* 12.0 16.1
Geographic region (IHS Service Unit) % %
Anchorage 34.0 46.8
Fairbanks 15.6 3.2
Yukon-Kuskokwim 16.3 24.2
Southeast 10.6 4.8
Kotzebue 7.1 4.8
Ketchikan 5.7 3.2
Norton Sound 5.7 4.8
Arctic Slope 2.8 3.2
Bristol Bay 2.1 4.8
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HPV 16 was detected as a single infection in 41.9% (26/
62). Eighteen (29%) specimens had oncogenic HPV other
than HPV 16 and 18. One (1.6%) specimen had only HPV
69 detected. Two HPV genotypes were detected in 12.9%
of specimens, and no specimens had more than 2 HPV
genotypes detected.
The histologic types identified from 62 specimens were:
squamous cell carcinoma (84%), adenocarcinoma (11%),
and carcinoma, not otherwise specified (5%). Among the
squamous cell carcinomas, HPV 16 was detected in 48%
and HPV 18 in 12%. Among the adenocarcinomas, HPV
16 was detected in 29% and HPV 18 in 29%.
Discussion
This study of cervical cancers in AN women found that
61% of tumors had evidence of HPV 16 or HPV 18. This
is similar to findings from other studies on US women, in
which approximately 70% of tumors were attributed to
HPV 16 or 18 (2,7). An HPV vaccine targeting oncogenic
genotypes 16 and 18 could reduce cervical cancers in AN
women by nearly two-thirds. If there is protection against
other vaccine-related oncogenic types, through cross-
protection or through new formulations of vaccine with
different virus-like particles, vaccination could result
in further reductions of cervical cancer (12,13). It is
important to note, one-third of HPV genotypes in our
specimen population contained other oncogenic non-
HPV 16 or non-HPV 18 genotypes alone (29%); types
not targeted by the current vaccines. Regular cervical
cancer screening for women at least 21 years or older
is currently recommended for all women regardless of
vaccination status.
Our study found some differences in HPV types in
cervical cancer compared to the only prior study in AN
women. In the prior study of cervical cancer specimens
from AN women diagnosed from 1980 to 1989, 53
formalin-fixed and paraffin-embedded cervical cancer
biopsies were assayed by PCR for 6 HPV genotypes
(16, 18, 31, 33, 35 and 45) (9); overall, 98% were HPV
positive. A higher percentage of HPV 16 alone (79% vs.
50%) and a lower percentage of HPV 18 alone were found
in the prior study compared to this study (4% vs. 15%).
The second most common HPV genotype in the earlier
Alaska study was HPV 33 (30%); in this study, only 5
cases (8%) contained HPV 33. Multiple HPV genotypes
were detected in 36.5% of cancer specimens in the earlier
study, while this study found multiple genotypes in only
12.9% of tissues. Our study used different methods to
reduce sample-to-sample viral carryover during thin-
section preparation and different DNA extraction meth-
ods that most likely account for these differences. Twelve
cases that were used in the prior study were retested in
this study, although they were not necessarily the same
tissue block. Of these 12, 9 (75%) were concordant for
HPV genotype. In 2 of the 3 discordant cases, HPV
genotype 16 was found by both methods, but the prior
study detected additional HPV types not found using
the current methods. The third discordant case revealed
genotype 33 using the current methods versus genotype
16 in the prior study. Thus, in cases tested in both studies,
the finding of a high percentage of multiple HPV geno-
types was not corroborated using the current methods.
One limitation of this study is that samples were selected
based on the availability at one hospital pathology
laboratory and may not be representative of all AN
women with cervical cancer. Of the 90 individuals who
received a diagnosis at ANMC, only 62 (69%) individuals
had a cervical cancer specimen available. Possible reasons
for unavailable tissue blocks include loss of specimen due
to errors in labeling or misfiling in trays in the pathology
laboratory, the storage box unlocatable in archives, or
the cervical cancer specimen was completely used up in
prior study. It is also important to note the classifica-
tion of high-risk types depends on the study and
methods. Munoz et al. classified 15 types as high risk,
or oncogenic, and another three as possible oncogenic,
types 26, 53 and 66 (7).
Studies in which HPV genotypes are detected in
invasive cervical cancer provide important information
to understand the impact HPV vaccines might have on
reducing cervical cancer in defined populations. To date,
most studies of different regions/ethnicities find simi-
lar proportions of cancers caused by HPV 16 or 18.
Table II. Number and percentage of HPV genotypes detected
in invasive cervical cancer specimens, Alaska Native women,
19802007 (N62)
HPV type Number %
16 26 41.9
18 6 9.6
166a 1 1.6
1618 2 3.2
1633 1 1.6
1654a 1 1.6
1868 1 1.6
31 1 1.6
3368 1 1.6
33 3 4.8
3959 1 1.6
45 3 4.8
58 1 1.6
59 5 8.0
73 2 3.2
82 1 1.6
69b 1 1.6
Total 57c 91.9
aLow-risk HPV type.
bNon-oncogenic HPV type.
cHPV was not detected in 5 specimens.
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Our study on AN women found a lower prevalence due to
HPV 16 or 18, but given smaller numbers this is con-
sistent with other studies. Evaluations of cancers due to
HPV 16 and 18 in specific populations as well as vaccine
impact monitoring on cancer reduction is warranted.
One-third of all cervical cancers are caused by HPV types
not prevented by vaccine, and provide support for con-
tinued Pap screening.
Conclusions
Overall, almost two-thirds (61.2%) of the archived
cervical cancers had detectible HPV types 16 or 18, a
finding similar to studies of US women. As expected,
a proportion of cancers would not be prevented by the
current vaccines. HPV vaccination and cervical cancer
screening are important prevention strategies for AN
women.
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